Mst 1 (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Mst 1, is an opioid analgesic presented as an oral formulation for systemic use. Classified as a Schedule II controlled substance in the EU, it provides analgesia for moderate to severe acute pain, cancer‑related pain, and post‑operative pain in adult patients requiring strong pain control.

GNH USA supplies Mst 1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with a focus on quality assurance, regulatory adherence, and reliable cold‑chain logistics where required.

Morphine Sulfate is an opioid analgesic used to manage pain through central µ‑opioid receptor activation.

Acute pain: provides rapid relief for severe injuries or medical procedures. Cancer pain: reduces tumor‑related nociceptive and neuropathic pain. Post‑operative pain: controls pain after surgical interventions. Severe chronic pain: offers long‑term relief when other analgesics are insufficient.

Morphine Sulfate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common after initiation. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness or sedation: central nervous system depression. - Dizziness or light‑headedness: especially when standing. - Sweating: increased perspiration. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: potentially life‑threatening reduction in breathing. - Severe hypotension: marked drop in blood pressure. - Anaphylactic reaction: rare but possible allergic response. - Dependence or addiction: risk of physical and psychological dependence. - Adrenal insufficiency: rare endocrine disturbance. - Seizures: uncommon but reported in overdose.

When prescribing Morphine Sulfate, clinicians should consider several safety measures.

Assess pain severity: ensure opioid therapy is appropriate for the level of pain. Monitor respiratory function: watch for signs of hypoventilation, especially in opioid‑naïve patients. Evaluate opioid tolerance: adjust dose based on prior exposure to opioids. Avoid concurrent CNS depressants: limit use with benzodiazepines, alcohol, or sedatives. Adjust dose in renal or hepatic impairment: reduce dosage or increase monitoring. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Morphine Sulfate can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Benzodiazepines or other CNS depressants: may cause profound sedation or respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome and hypertensive crisis. - Alcohol: potentiates central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels. - Diuretics: can enhance hypotensive effects. - Antihistamines or anticholinergics: may increase sedation or anticholinergic burden.